Ensemble analyses improve signatures of tumour hypoxia and reveal inter-platform differences

BMC Bioinformatics

Volumn 15, Issue 1, 2014, Pages

  Fox, Natalie S ^a,d   Starmans, Maud H W ^a,b   Haider, Syed ^a,c   Lambin, Philippe ^b   Boutros, Paul C ^a,d,e  

^a ONTARIO INSTITUTE FOR CANCER RESEARCH   (Canada)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOMARKERS; TUMORS;

CLINICAL APPLICATION; ENSEMBLE CLASSIFICATION; ENSEMBLE TECHNIQUES; PRE-PROCESSING; PRE-PROCESSING METHOD; REPRODUCIBILITIES;

CLASSIFICATION (OF INFORMATION);

ALGORITHM; ARTICLE; CELL HYPOXIA; GENE EXPRESSION REGULATION; HUMAN; NEOPLASM; PATHOLOGY; PROGNOSIS; REPRODUCIBILITY; TISSUE MICROARRAY;

ALGORITHMS; CELL HYPOXIA; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS; PROGNOSIS; REPRODUCIBILITY OF RESULTS; TISSUE ARRAY ANALYSIS;

EID: 84902548920     PISSN: None     EISSN: 14712105     Source Type: Journal    
DOI: 10.1186/1471-2105-15-170     Document Type: Article

References (44)

1. Polyak K. Heterogeneity in breast cancer. J Clin Invest 2011, 121:3786-3788. 10.1172/JCI60534, 3195489, 21965334.
2. Curtis C, Shah SP, Chin S-F, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, Gräf S, Ha G, Haffari G, Bashashati A, Russell R, McKinney S, Langerød A, Green A, Provenzano E, Wishart G, Pinder S, Watson P, Markowetz F, Murphy L, Ellis I, Purushotham A, Børresen-Dale A-L, Brenton JD, Tavaré S, et al. METABRIC Group The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012, 486:346-352. 3440846, 22522925, METABRIC Group.
3. Russnes HG, Navin N, Hicks J, Borresen-Dale A-L. Insight into the heterogeneity of breast cancer through next-generation sequencing. J Clin Invest 2011, 121:3810-3818. 10.1172/JCI57088, 3195464, 21965338.
4. Van 't Veer LJ, Bernards R. Enabling personalized cancer medicine through analysis of gene-expression patterns. Nature 2008, 452:564-570. 10.1038/nature06915, 18385730.
5. Lambin P, van Stiphout RGPM, Starmans MHW, Rios-Velazquez E, Nalbantov G, Aerts HJWL, Roelofs E, van Elmpt W, Boutros PC, Granone P, Valentini V, Begg AC, De Ruysscher D, Dekker A. Predicting outcomes in radiation oncology-multifactorial decision support systems. Nat Rev Clin Oncol 2013, 10:27-40.
6. Abba M, Lacunza E, Butti M, Aldaz C. Breast cancer biomarker discovery in the functional Genomic Age: a systematic review of 42 gene expression signatures. Biomark Insights 2010, 5:103-118. 2978930, 21082037.
7. Kern SE. Why your New cancer biomarker May never work: recurrent patterns and remarkable diversity in biomarker failures. Cancer Res 2012, 72:6097-6101. 10.1158/0008-5472.CAN-12-3232, 3513583, 23172309.
8. Diamandis EP. The failure of protein cancer biomarkers to reach the clinic: why, and what can be done to address the problem?. BMC Med 2012, 10:87. 10.1186/1741-7015-10-87, 3425158, 22876833.
9. Starmans MH, Pintilie M, John T, Der SD, Shepherd FA, Jurisica I, Lambin P, Tsao M-S, Boutros PC. Exploiting the noise: improving biomarkers with ensembles of data analysis methodologies. Genome Med 2012, 4:84. 10.1186/gm385, 3580418, 23146350.
10. Goel S, Duda DG, Xu L, Munn LL, Boucher Y, Fukumura D, Jain RK. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev 2011, 91:1071-1121. 10.1152/physrev.00038.2010, 3258432, 21742796.
11. Brown JM, Wilson WR. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 2004, 4:437-447. 10.1038/nrc1367, 15170446.
12. Wouters BG, van den Beucken T, Magagnin MG, Lambin P, Koumenis C. Targeting hypoxia tolerance in cancer. Drug Resist Updat 2004, 7:25-40. 10.1016/j.drup.2003.12.004, 15072769.
13. Buffa FM, Harris AL, West CM, Miller CJ. Large meta-analysis of multiple cancers reveals a common, compact and highly prognostic hypoxia metagene. Br J Cancer 2010, 102:428-435. 10.1038/sj.bjc.6605450, 2816644, 20087356.
14. Chi J-T, Wang Z, Nuyten DSA, Rodriguez EH, Schaner ME, Salim A, Wang Y, Kristensen GB, Helland T, Børresen-Dale A-L, Giaccia A, Longaker MT, Hastie T, Yang GP, van de Vijver MJ, Brown PO. Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med 2006, 3:e47. 10.1371/journal.pmed.0030047, 1334226, 16417408.
15. Elvidge GP, Glenny L, Appelhoff RJ, Ratcliffe PJ, Ragoussis J, Gleadle JM. Concordant regulation of gene expression by hypoxia and 2-oxoglutarate-dependent dioxygenase inhibition: the role of HIF-1alpha, HIF-2alpha, and other pathways. J Biol Chem 2006, 281:15215-15226. 10.1074/jbc.M511408200, 16565084.
16. Hu Z, Fan C, Livasy C, He X, Oh DS, Ewend MG, Carey LA, Subramanian S, West R, Ikpatt F, Olopade OI, van de Rijn M, Perou CM. A compact VEGF signature associated with distant metastases and poor outcomes. BMC Med 2009, 7:9. 10.1186/1741-7015-7-9, 2671523, 19291283.
17. Seigneuric R, Starmans MHW, Fung G, Krishnapuram B, Nuyten DSA, van Erk A, Magagnin MG, Rouschop KM, Krishnan S, Rao RB, Evelo CTA, Begg AC, Wouters BG, Lambin P. Impact of supervised gene signatures of early hypoxia on patient survival. Radiother Oncol 2007, 83:374-382. 10.1016/j.radonc.2007.05.002, 17532074.
18. Sørensen BS, Toustrup K, Horsman MR, Overgaard J, Alsner J. Identifying pH independent hypoxia induced genes in human squamous cell carcinomas in vitro. Acta Oncol 2010, 49:895-905. 10.3109/02841861003614343, 20429727.
19. Winter SC, Buffa FM, Silva P, Miller C, Valentine HR, Turley H, Shah KA, Cox GJ, Corbridge RJ, Homer JJ, Musgrove B, Slevin N, Sloan P, Price P, West CML, Harris AL. Relation of a hypoxia metagene derived from head and neck cancer to prognosis of multiple cancers. Cancer Res 2007, 67:3441-3449. 10.1158/0008-5472.CAN-06-3322, 17409455.
20. Starmans MHW, Chu KC, Haider S, Nguyen F, Seigneuric R, Magagnin MG, Koritzinsky M, Kasprzyk A, Boutros PC, Wouters BG, Lambin P. The prognostic value of temporal in vitro and in vivo derived hypoxia gene-expression signatures in breast cancer. Radiother Oncol 2012, 102:436-443. 10.1016/j.radonc.2012.02.002, 22356756.
21. Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A, Pawitan Y, Hall P, Klaar S, Liu ET, Bergh J. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci U S A 2005, 102:13550-13555. 10.1073/pnas.0506230102, 1197273, 16141321.
22. Schmidt M, Petry IB, Böhm D, Lebrecht A, von Törne C, Gebhard S, Gerhold-Ay A, Cotarelo C, Battista M, Schormann W, Freis E, Selinski S, Ickstadt K, Rahnenführer J, Sebastian M, Schuler M, Koelbl H, Gehrmann M, Hengstler JG. Ep-CAM RNA expression predicts metastasis-free survival in three cohorts of untreated node-negative breast cancer. Breast Cancer Res Treat 2011, 125:637-646. 10.1007/s10549-010-0856-5, 20352488.
23. Wang Y, Klijn JGM, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME, Yu J, Jatkoe T, Berns EMJJ, Atkins D, Foekens JA. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005, 365:671-679. 10.1016/S0140-6736(05)17947-1, 15721472.
24. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, Nordgren H, Farmer P, Praz V, Haibe-Kains B, Desmedt C, Larsimont D, Cardoso F, Peterse H, Nuyten D, Buyse M, de Vijver MJV, Bergh J, Piccart M, Delorenzi M. Gene expression profiling in breast cancer: understanding the molecular basis of Histologic grade to improve prognosis. JNCI J Natl Cancer Inst 2006, 98:262-272.
25. Pawitan Y, Bjöhle J, Amler L, Borg A-L, Egyhazi S, Hall P, Han X, Holmberg L, Huang F, Klaar S, Liu ET, Miller L, Nordgren H, Ploner A, Sandelin K, Shaw PM, Smeds J, Skoog L, Wedrén S, Bergh J. Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res 2005, 7:R953. 10.1186/bcr1325, 1410752, 16280042.
26. Symmans WF, Hatzis C, Sotiriou C, Andre F, Peintinger F, Regitnig P, Daxenbichler G, Desmedt C, Domont J, Marth C, Delaloge S, Bauernhofer T, Valero V, Booser DJ, Hortobagyi GN, Pusztai L. Genomic index of sensitivity to endocrine therapy for breast cancer. J Clin Oncol 2010, 28:4111-4119. 10.1200/JCO.2010.28.4273, 2953969, 20697068.
27. Desmedt C, Piette F, Loi S, Wang Y, Lallemand F, Haibe-Kains B, Viale G, Delorenzi M, Zhang Y, d' Assignies MS, Bergh J, Lidereau R, Ellis P, Harris AL, Klijn JGM, Foekens JA, Cardoso F, Piccart MJ, Buyse M, Sotiriou C. Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res 2007, 13:3207-3214. 10.1158/1078-0432.CCR-06-2765, 17545524.
28. Zhang Y, Sieuwerts AM, McGreevy M, Casey G, Cufer T, Paradiso A, Harbeck N, Span PN, Hicks DG, Crowe J, Tubbs RR, Budd GT, Lyons J, Sweep FCGJ, Schmitt M, Schittulli F, Golouh R, Talantov D, Wang Y, Foekens JA. The 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy. Breast Cancer Res Treat 2009, 116:303-309. 10.1007/s10549-008-0183-2, 18821012.
29. Sabatier R, Finetti P, Cervera N, Lambaudie E, Esterni B, Mamessier E, Tallet A, Chabannon C, Extra J-M, Jacquemier J, Viens P, Birnbaum D, Bertucci F. A gene expression signature identifies two prognostic subgroups of basal breast cancer. Breast Cancer Res Treat 2011, 126:407-420. 10.1007/s10549-010-0897-9, 20490655.
30. Kao K-J, Chang K-M, Hsu H-C, Huang AT. Correlation of microarray-based breast cancer molecular subtypes and clinical outcomes: implications for treatment optimization. BMC Cancer 2011, 11:143. 10.1186/1471-2407-11-143, 3094326, 21501481.
31. Bos PD, Zhang XH-F, Nadal C, Shu W, Gomis RR, Nguyen DX, Minn AJ, Van de Vijver M, Gerald W, Foekens JA, Massague J. Genes that mediate breast cancer metastasis to the brain. Nature 2009, 459:1005-1009. 10.1038/nature08021, 2698953, 19421193.
32. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003, 4:249-264. 10.1093/biostatistics/4.2.249, 12925520.
33. Hubbell E, Liu W-M, Mei R. Robust estimators for expression analysis. Bioinformatics 2002, 18:1585-1592. 10.1093/bioinformatics/18.12.1585, 12490442.
34. Li C, Hung Wong W. Model-based analysis of oligonucleotide arrays: model validation, design issues and standard error application. Genome Biol 2001, 2:research0032.1-research0032.11.
35. Wu Z, Irizarry RA. Stochastic models inspired by hybridization theory for short oligonucleotide arrays. J Comput Biol 2005, 12:882-893. 10.1089/cmb.2005.12.882, 16108723.
36. Dai M, Wang P, Boyd AD, Kostov G, Athey B, Jones EG, Bunney WE, Myers RM, Speed TP, Akil H, Watson SJ, Meng F. Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data. Nucleic Acids Res 2005, 33:e175. 10.1093/nar/gni179, 1283542, 16284200.
37. Boutros PC, Ewing AD, Ellrott K, Norman TC, Dang KK, Hu Y, Kellen MR, Suver C, Bare JC, Stein LD, Spellman PT, Stolovitzky G, Friend SH, Margolin AA, Stuart JM. Global optimization of somatic variant identification in cancer genomes with a global community challenge. Nat Genet 2014, 46:318-319. 10.1038/ng.2932, 4035501, 24675517.
38. Shi L, Campbell G, Jones WD, Campagne F, Wen Z, Walker SJ, Su Z, Chu T-M, Goodsaid FM, Pusztai L, Shaughnessy JD, Oberthuer A, Thomas RS, Paules RS, Fielden M, Barlogie B, Chen W, Du P, Fischer M, Furlanello C, Gallas BD, Ge X, Megherbi DB, Symmans WF, Wang MD, Zhang J, Bitter H, Brors B, Bushel PR, Bylesjo M, et al. The MicroArray quality control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol 2010, 28:827-838. 10.1038/nbt.1665, 3315840, 20676074.
39. Verhaak RGW, Staal FJT, Valk PJM, Lowenberg B, Reinders MJT, de Ridder D. The effect of oligonucleotide microarray data pre-processing on the analysis of patient-cohort studies. BMC Bioinforma 2006, 7:105.
40. Bolstad BM, Irizarry RA, Åstrand M, Speed TP. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 2003, 19:185-193. 10.1093/bioinformatics/19.2.185, 12538238.
41. Subramanian J, Simon R. Gene expression-based prognostic signatures in lung cancer: ready for clinical use?. J Natl Cancer Inst 2010, 102:464-474. 10.1093/jnci/djq025, 2902824, 20233996.
42. Boutros PC, Lau SK, Pintilie M, Liu N, Shepherd FA, Der SD, Tsao M-S, Penn LZ, Jurisica I. Prognostic gene signatures for non-small-cell lung cancer. PNAS 2009, 106:2824-2828. 10.1073/pnas.0809444106, 2636731, 19196983.
43. Starmans MHW, Fung G, Steck H, Wouters BG, Lambin P. A simple but highly effective approach to evaluate the prognostic performance of gene expression signatures. PLoS ONE 2011, 6:e28320. 10.1371/journal.pone.0028320, 3233554, 22163293.
44. Venet D, Dumont JE, Detours V. Most random gene expression signatures are significantly associated with breast cancer outcome. PLoS Comput Biol 2011, 7:e1002240. 10.1371/journal.pcbi.1002240, 3197658, 22028643.